Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 14/20 | 0.57 |
| ▸ | PPARA | Q07869 | 4/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | VDR | P11473 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13210251 | 0.85 | FBP1 (0.41) | FBP1PPARAPPARGVDR | |
| SCHEMBL1549824 | 0.84 | FBP1 (0.58) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL9701146 | 0.82 | FBP1 (0.57) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL2431952 | 0.82 | FBP1 (0.62) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL7984260 | 0.82 | TSHR (0.64) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL22005942 | 0.82 | FBP1 (0.57) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL4102953 | 0.81 | FBP1 (0.56) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL1550208 | 0.81 | FBP1 (0.56) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL14527819 | 0.81 | FBP1 (0.56) | FBP1PPARAABCB11CYP1A2CYP3A4 | |
| SCHEMBL4681712 | 0.81 | FBP1 (0.56) | FBP1PPARAABCB11CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791812-B1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-04 | — | — | EP | disclosed |
| EP-1794116-B1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-03 | — | — | EP | disclosed |
| US-8242173-B2 | modulators of peroxisome proliferator activated receptors; treating diabetes, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cardiovascular diseases; dyslipidema; [4-[[2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]-acetic acid | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8242173-B2 | modulators of peroxisome proliferator activated receptors; treating diabetes, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cardiovascular diseases; dyslipidema; [4-[[2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]-acetic acid | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-14 | — | — | US | disclosed |
| US-7875744-B2 | modulators of peroxisome proliferator activated receptors; treating diabetes, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cardiovascular diseases; dyslipidema; [4-[[2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]-acetic acid | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-25 | — | — | US | disclosed |
| US-7875744-B2 | modulators of peroxisome proliferator activated receptors; treating diabetes, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cardiovascular diseases; dyslipidema; [4-[[2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]-acetic acid | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-25 | — | — | US | disclosed |
| US-7875744-B2 | modulators of peroxisome proliferator activated receptors; treating diabetes, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cardiovascular diseases; dyslipidema; [4-[[2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]-acetic acid | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-25 | — | — | US | disclosed |
| US-20100331406-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | TUFTS COLLEGE | 2010-12-30 | — | — | US | disclosed |
| US-20100331406-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | TUFTS COLLEGE | 2010-12-30 | — | — | US | disclosed |
| US-7812053-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICALS NV (BE) | 2010-10-12 | — | — | US | disclosed |
| WO-2006031969-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | WO | disclosed |
| WO-2006032023-A2 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | WO | disclosed |
| US-7015329-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N. V. (BE) | 2006-03-21 | — | — | US | disclosed |
| US-20060058382-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N. V. (BE) | 2006-03-16 | — | — | US | disclosed |
| US-20060058393-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-16 | — | — | US | disclosed |
| WO-2005041959-A1 | PHENOXYACETIC ACIDS DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) DUAL AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-12 | — | — | WO | disclosed |
| US-20050096362-A1 | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-05 | — | — | US | disclosed |
| US-20040077659-A1 | Method for treating ppar gamma mediated diseases or conditions | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| EP-1368011-A1 | METHOD FOR TREATING PPAR GAMMA MEDIATED DISEASES | SmithKline Beecham Corporation (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002067912-A2 | METHOD FOR TREATING PPAR GAMMA MEDIATED DISEASES OR CONDITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058382-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | FBP1 743/4885PPARA 1/4885ABCB11 1390/4885 |
| US-20060058393-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | FBP1 743/4885PPARA 1/4885ABCB11 1390/4885 |
| US-20050096362-A1 | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | FBP1 743/4885PPARA 1/4885ABCB11 1390/4885 |
| US-20040077659-A1 | Method for treating ppar gamma mediated diseases or conditions | PPARG, PPARA, PPARD | FBP1 1472/4885PPARA 2/4885ABCB11 2146/4885 |
| US-20100331406-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | FBP1 743/4885PPARA 1/4885ABCB11 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.